
Abivax Begins Enrollment in Phase 2b Study of Experimental Ulcerative Colitis Treatment
According to a press release from French biotechnology company Abivax, the Company has successfully begun recruitment for its phase 2b clinical study of ABX464, its experimental once-a-day ulcerative colitis medication.…